Maoyu Extract Suppresses Non-Small Cell Lung Cancer Progression via PI3K/AKT Signaling Blockade: An Integrated Network Pharmacology and Experimental Validation Study
Applied Biochemistry and Biotechnology · 2026-12 · 198 (12) · 10749-10771
DOI: 10.1007/s12010-026-05923-3 ↗At a glance
Validierungsstudie in Applied Biochemistry and Biotechnology, published online on 2026-10-29. Written by Min Song and 5 co-authors. Institution: College of Pharmacy, Xinyang Agriculture and Forestry University, Xinyang, 45000, Henan, China. Major MEDLINE topics: Proto-Oncogene Proteins c-akt, Carcinoma, Non-Small-Cell Lung, Signal Transduction, Phosphatidylinositol 3-Kinases. 87 references. Funded by: Natural Science Foundation of Henan Province, Key Research and Development Project of Henan Province, Key Research Project of Higher Education Institutions in Henan Province.
Abstract (original language)
Non-small cell lung cancer (NSCLC) is a leading cause of global cancer mortality. Maoyu extract (MY) is a traditional Chinese medicine formulation comprising Ranunculus ternatus Thunb. and Houttuynia cordata Thunb., used traditionally to treat inflammatory lung ailments and nodules. This study aims to systematically investigate the anti-NSCLC efficacy of Maoyu extract and elucidate its underlying molecular mechanisms, specifically focusing on the PI3K/AKT signaling axis. Active compounds and targets were screened using the TCMSP database and validated via molecular docking. Predicted mechanisms were verified in vitro using A549 and NCI-H1299 cell lines and in vivo using a syngeneic Lewis lung carcinoma (LLC) mouse model. Network analysis identified 15 active compounds (including β-sitosterol, kaempferol, and quercetin) and 197 targets. MY significantly inhibited cell proliferation, induced apoptosis, and blocked the PI3K/AKT axis. In the LLC model, MY reduced tumor volume by 56.77%, matching cisplatin's efficacy without inducing significant body weight loss. Maoyu extract exerts potent anti-NSCLC effects by suppressing proliferation and inducing apoptosis through the targeted blockade of the PI3K/AKT signaling axis, providing a scientific basis for its traditional use.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- College of Pharmacy, Xinyang Agriculture and Forestry University, Xinyang, 45000, Henan, China.
- College of Pharmacy, Xinyang Agriculture and Forestry University, Xinyang, 45000, Henan, China. zczh9961@outlook.com.
Funding
- Natural Science Foundation of Henan Province
- Key Research and Development Project of Henan Province
- Key Research Project of Higher Education Institutions in Henan Province
- Scientific and Technological Fund for Young Scientists of Xinyang Agriculture and Forestry University
Cite
APA
Song, M., Tan, J., Liu, L., Zhang, Y., Wang, B., & Zhai, Y. (2026). Maoyu Extract Suppresses Non-Small Cell Lung Cancer Progression via PI3K/AKT Signaling Blockade: An Integrated Network Pharmacology and Experimental Validation Study. Applied Biochemistry and Biotechnology, 198(12), 10749-10771. https://doi.org/10.1007/s12010-026-05923-3
Vancouver
Song M, Tan J, Liu L, Zhang Y, Wang B, Zhai Y. Maoyu Extract Suppresses Non-Small Cell Lung Cancer Progression via PI3K/AKT Signaling Blockade: An Integrated Network Pharmacology and Experimental Validation Study. Applied Biochemistry and Biotechnology. 2026;198(12):10749-10771. doi:10.1007/s12010-026-05923-3
BibTeX
@article{Song2026,
author = {Song, Min and Tan, Jinlong and Liu, Luyi and Zhang, Yuzhen and Wang, Binbin and Zhai, Yingying},
title = {Maoyu Extract Suppresses Non-Small Cell Lung Cancer Progression via PI3K/AKT Signaling Blockade: An Integrated Network Pharmacology and Experimental Validation Study},
journal = {Applied Biochemistry and Biotechnology},
year = {2026},
volume = {198},
number = {12},
pages = {10749--10771},
doi = {10.1007/s12010-026-05923-3}
}
EUVIMED